[go: up one dir, main page]

MX2019003090A - Compuestos de microarn y metodos para modular la actividad de mir-21. - Google Patents

Compuestos de microarn y metodos para modular la actividad de mir-21.

Info

Publication number
MX2019003090A
MX2019003090A MX2019003090A MX2019003090A MX2019003090A MX 2019003090 A MX2019003090 A MX 2019003090A MX 2019003090 A MX2019003090 A MX 2019003090A MX 2019003090 A MX2019003090 A MX 2019003090A MX 2019003090 A MX2019003090 A MX 2019003090A
Authority
MX
Mexico
Prior art keywords
activity
mir
methods
compositions
modulating mir
Prior art date
Application number
MX2019003090A
Other languages
English (en)
Other versions
MX393138B (es
Inventor
Bhat Balkrishen
Original Assignee
Regulus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regulus Therapeutics Inc filed Critical Regulus Therapeutics Inc
Publication of MX2019003090A publication Critical patent/MX2019003090A/es
Publication of MX393138B publication Critical patent/MX393138B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)

Abstract

En la presente se describen composiciones y métodos para la inhibición de la actividad de miR-21. Las composiciones tienen determinados patrones de modificación de nucleósidos que proporcionan potentes inhibidores de la actividad de miR-21. Las composiciones pueden usarse para inhibir miR-21 y también para tratar enfermedades asociadas con la expresión anormal de miR-21, tal como fibrosis y cáncer.
MX2019003090A 2011-04-25 2012-04-25 Compuestos de microarn y metodos para modular la actividad de mir-21. MX393138B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161478767P 2011-04-25 2011-04-25
US201161565779P 2011-12-01 2011-12-01
PCT/US2012/034880 WO2012148952A1 (en) 2011-04-25 2012-04-25 Microrna compounds and methods for modulating mir-21 activity

Publications (2)

Publication Number Publication Date
MX2019003090A true MX2019003090A (es) 2019-07-18
MX393138B MX393138B (es) 2025-03-24

Family

ID=46025979

Family Applications (5)

Application Number Title Priority Date Filing Date
MX2013012452A MX2013012452A (es) 2011-04-25 2012-04-25 Compuestos de microarn y metodos para modular la actividad de mir-21.
MX2019003090A MX393138B (es) 2011-04-25 2012-04-25 Compuestos de microarn y metodos para modular la actividad de mir-21.
MX2022006595A MX2022006595A (es) 2011-04-25 2013-10-23 Compuestos de microarn y metodos para modular la actividad de mir-21.
MX2022000212A MX2022000212A (es) 2011-04-25 2013-10-23 Compuestos de microarn y metodos para modular la actividad de mir-21.
MX2019003089A MX2019003089A (es) 2011-04-25 2013-10-23 Compuestos de microarn y metodos para modular la actividad de mir-21.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013012452A MX2013012452A (es) 2011-04-25 2012-04-25 Compuestos de microarn y metodos para modular la actividad de mir-21.

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2022006595A MX2022006595A (es) 2011-04-25 2013-10-23 Compuestos de microarn y metodos para modular la actividad de mir-21.
MX2022000212A MX2022000212A (es) 2011-04-25 2013-10-23 Compuestos de microarn y metodos para modular la actividad de mir-21.
MX2019003089A MX2019003089A (es) 2011-04-25 2013-10-23 Compuestos de microarn y metodos para modular la actividad de mir-21.

Country Status (30)

Country Link
US (7) US9181547B2 (es)
EP (3) EP3933040A1 (es)
JP (2) JP6320292B2 (es)
KR (2) KR102055172B1 (es)
CN (3) CN113249381A (es)
AU (4) AU2012249851B2 (es)
BR (1) BR112013027187A2 (es)
CA (2) CA2833615C (es)
CL (1) CL2013003105A1 (es)
CO (1) CO6821889A2 (es)
CY (1) CY1120304T1 (es)
DK (2) DK2702155T3 (es)
EA (1) EA025894B1 (es)
ES (2) ES2621863T3 (es)
HR (2) HRP20170557T2 (es)
HU (2) HUE031595T2 (es)
IL (3) IL229032B (es)
LT (2) LT3211082T (es)
MX (5) MX2013012452A (es)
MY (2) MY175336A (es)
NZ (1) NZ717921A (es)
PH (1) PH12013502199A1 (es)
PL (2) PL3211082T3 (es)
PT (2) PT3211082T (es)
RS (1) RS61775B1 (es)
SG (1) SG194636A1 (es)
SI (2) SI2702155T1 (es)
TW (2) TWI698445B (es)
UA (1) UA115652C2 (es)
WO (1) WO2012148952A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2503765T3 (es) 2004-11-12 2014-10-07 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES2621863T3 (es) 2011-04-25 2017-07-05 Regulus Therapeutics Inc. Compuestos de microARN y métodos para modular la actividad de miR-21
WO2013153082A1 (en) * 2012-04-10 2013-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of nonalcoholic steatohepatitis
AR090825A1 (es) 2012-04-25 2014-12-10 Regulus Therapeutics Inc COMPUESTO DE microARN Y METODOS DE MODULACION DE LA ACTIVIDAD DE miR-21
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
MY173826A (en) 2012-11-15 2020-02-24 Roche Innovation Ct Copenhagen As Oligonucleotide conjugates
CA2908939C (en) * 2013-05-01 2023-08-22 Balkrishen Bhat Microrna compounds and methods for modulating mir-122
WO2015061536A1 (en) * 2013-10-25 2015-04-30 Regulus Therapeutics Inc. Microrna compounds and methods for modulating mir-21 activity
KR101625755B1 (ko) 2013-11-18 2016-05-30 울산대학교 산학협력단 ｍｉＲＮＡ 스폰지 및 이의 용도
JP2017505623A (ja) * 2014-01-30 2017-02-23 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 生物切断性コンジュゲートを有するポリオリゴマー化合物
CN105734127A (zh) * 2016-02-29 2016-07-06 上海中医药大学 miR-21-3p在制备用于检测早期急性肾损伤的试剂中的用途
WO2017187426A1 (en) 2016-04-29 2017-11-02 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC Exosomes for delivery of therapeutic agents
FI3684949T3 (fi) 2017-09-22 2024-07-17 Univ Washington Solumolekyylien kombinatorinen in situ -leimaaminen
CN108148911B (zh) * 2018-03-02 2019-11-05 广州医科大学附属第二医院 miR-582在制备前列腺癌骨转移的诊断、预后试剂盒及药物中的应用
TWI854980B (zh) 2018-05-08 2024-09-11 美商雷格勒斯治療公司 用於調節mir-122之微小rna化合物及方法
CN110747266A (zh) * 2018-07-23 2020-02-04 深圳先进技术研究院 miR-21和miR-21拮抗剂在抑制预防/治疗1型糖尿病中的应用
CN109880907A (zh) * 2019-03-26 2019-06-14 中国人民解放军第八一医院 一种肝癌细胞侵袭转移的分子机制研究方法
US11965162B2 (en) 2020-04-16 2024-04-23 The Johns Hopkins University MicroRNA and inhibitors thereof and methods of treatment
WO2022165092A1 (en) * 2021-01-29 2022-08-04 Angion Biomedica Corp. Methods for treatment of fibrotic diseases
WO2025110217A1 (ja) * 2023-11-22 2025-05-30 国立大学法人東海国立大学機構 嚢胞性腎疾患の予防及び／又は治療剤
CN120505413A (zh) * 2025-07-15 2025-08-19 湖南工程学院 一种基于引物交换反应和G-四链体检测AKI相关miRNA的探针体系及方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69935853T2 (de) 1998-05-22 2008-01-10 Boys Town National Research Hospital, Omaha Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1-inhibitoren zur behandlung von nierenkrankheiten
US20060008817A1 (en) * 2000-12-08 2006-01-12 Invitrogen Corporation Methods and compositions for generating recombinant nucleic acid molecules
CA2937159C (en) 2001-09-28 2017-11-28 Thomas Tuschl Microrna molecules
WO2004041889A2 (en) 2002-11-05 2004-05-21 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
EP1648914A4 (en) * 2003-07-31 2009-12-16 Regulus Therapeutics Inc OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA
EP1661905B9 (en) 2003-08-28 2012-12-19 IMANISHI, Takeshi Novel artificial nucleic acids of n-o bond crosslinkage type
WO2006020768A2 (en) 2004-08-10 2006-02-23 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides
US20080187508A1 (en) 2004-09-08 2008-08-07 Boys Town National Research Hospital Treatment of Golmerular Basement Membrane Disease Involving Matrix Metalloproteinase-12
ES2503765T3 (es) 2004-11-12 2014-10-07 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
EP1838870A2 (en) 2004-12-29 2007-10-03 Exiqon A/S NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAs
US6995235B1 (en) 2005-05-02 2006-02-07 Univation Technologies, Llc Methods of producing polyolefins and films therefrom
EP1931780B1 (en) * 2005-08-29 2016-01-06 Regulus Therapeutics Inc. Antisense compounds having enhanced anti-microrna activity
EP2388328A1 (en) 2006-01-27 2011-11-23 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
EP1984381B1 (en) 2006-01-27 2010-09-29 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
CA3042781C (en) * 2006-04-03 2021-10-19 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
ES2569558T3 (es) * 2006-04-03 2016-05-11 Roche Innovation Center Copenhagen A/S Composición farmacéutica que comprende oligonucleótidos antisentido anti-ARNmi
DK2068886T3 (da) 2006-10-03 2013-11-18 Tekmira Pharmaceuticals Corp Lipidholdige præparater
EP2476762B1 (de) 2006-10-09 2014-01-08 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) zur Diagnose und Therapie von Herzerkrankungen
AU2007333107A1 (en) 2006-12-08 2008-06-19 Asuragen, Inc. miR-21 regulated genes and pathways as targets for therapeutic intervention
WO2008086807A2 (en) 2007-01-19 2008-07-24 Exiqon A/S Mediated cellular delivery of lna oligonucleotides
WO2008150729A2 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
WO2008151631A2 (en) 2007-06-15 2008-12-18 Exiqon A/S Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
DK2176280T4 (en) 2007-07-05 2015-07-20 Isis Pharmaceuticals Inc 6-Disubstituerede bicykliske nukleinsyreanaloge
CA2701547C (en) * 2007-10-04 2020-03-10 Santaris Pharma A/S Oligonucleotides which target and inhibit micrornas
WO2009058907A2 (en) * 2007-10-29 2009-05-07 Isis Pharmaceuticals, Inc. Targeting micrornas for the treatment of liver cancer
WO2009091972A2 (en) 2008-01-18 2009-07-23 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof
EP2249874A1 (en) 2008-02-08 2010-11-17 ProSensa Holding BV Methods and means for treating dna repeat instability associated genetic disorders
EP2096171A1 (en) * 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
US8404659B2 (en) 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
AU2010218147A1 (en) 2009-02-26 2011-10-20 The Government Of The United States Of America As Represented By The Secretary Of The Dept. Of Health & Human Services MicroRNAs in never-smokers and related materials and methods
MX2011013176A (es) 2009-06-08 2012-04-30 Miragen Therapeutics Motivos de modificación química para inhibidores y miméticos del miarn.
WO2011126842A2 (en) 2010-03-30 2011-10-13 Regulus Therapeutics Inc. Targeting micrornas for the treatment of cardiac disorders
ES2621863T3 (es) 2011-04-25 2017-07-05 Regulus Therapeutics Inc. Compuestos de microARN y métodos para modular la actividad de miR-21
WO2013013165A2 (en) 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus
AR090825A1 (es) 2012-04-25 2014-12-10 Regulus Therapeutics Inc COMPUESTO DE microARN Y METODOS DE MODULACION DE LA ACTIVIDAD DE miR-21
EP3354734B1 (en) 2012-06-21 2020-06-10 Miragen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
JP6352269B2 (ja) 2012-09-26 2018-07-04 ミルクス セラピューティクス アクティーゼルスカブＭｉｒｒｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａ／Ｓ オフターゲットプロファイルの改善されたオリゴマー
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта

Also Published As

Publication number Publication date
BR112013027187A2 (pt) 2017-06-06
HUE031595T2 (en) 2017-07-28
DK2702155T3 (en) 2017-05-01
AU2022203067A1 (en) 2022-05-26
IL229032A0 (en) 2013-12-31
US20200291400A1 (en) 2020-09-17
MY187685A (en) 2021-10-11
JP2014518619A (ja) 2014-08-07
HRP20170557T1 (hr) 2017-06-16
HRP20170557T2 (hr) 2020-02-21
EP3933040A1 (en) 2022-01-05
IL229032B (en) 2021-01-31
HRP20210616T1 (hr) 2021-05-28
HK1243130A1 (en) 2018-07-06
EP2702155B9 (en) 2020-01-01
EP2702155B1 (en) 2017-02-01
HUE054129T2 (hu) 2021-08-30
MX2022000212A (es) 2022-04-01
IL273381A (en) 2020-05-31
IL266529A (en) 2019-07-31
PT3211082T (pt) 2021-04-28
TW201300404A (zh) 2013-01-01
SG194636A1 (en) 2013-12-30
US12331294B2 (en) 2025-06-17
EP2702155A1 (en) 2014-03-05
WO2012148952A1 (en) 2012-11-01
CN113249381A (zh) 2021-08-13
AU2017219156A1 (en) 2017-09-21
MX393138B (es) 2025-03-24
US9181547B2 (en) 2015-11-10
PL2702155T3 (pl) 2017-09-29
US20140329887A1 (en) 2014-11-06
CY1120304T1 (el) 2019-07-10
ES2868950T3 (es) 2021-10-22
EA025894B1 (ru) 2017-02-28
CA3165397A1 (en) 2012-11-01
CA2833615A1 (en) 2012-11-01
CN103620035A (zh) 2014-03-05
CO6821889A2 (es) 2013-12-31
MX2022006595A (es) 2022-07-01
NZ616748A (en) 2016-03-31
US20180155719A1 (en) 2018-06-07
LT3211082T (lt) 2021-05-10
US9790496B2 (en) 2017-10-17
MY175336A (en) 2020-06-19
PH12013502199A1 (en) 2014-01-27
TWI607016B (zh) 2017-12-01
US8912161B2 (en) 2014-12-16
AU2012249851A1 (en) 2013-10-31
AU2012249851B2 (en) 2017-06-08
AU2020201403A1 (en) 2020-03-12
US20120270928A1 (en) 2012-10-25
CN113151272A (zh) 2021-07-23
ES2621863T9 (es) 2020-02-13
US20160138016A1 (en) 2016-05-19
JP2018121646A (ja) 2018-08-09
CA2833615C (en) 2022-08-30
ES2621863T3 (es) 2017-07-05
KR20140033062A (ko) 2014-03-17
US20140107183A1 (en) 2014-04-17
RS61775B1 (sr) 2021-05-31
KR20190063482A (ko) 2019-06-07
US20220098583A1 (en) 2022-03-31
MX2013012452A (es) 2014-11-21
NZ717921A (en) 2017-09-29
EA201391492A1 (ru) 2014-04-30
PL3211082T3 (pl) 2021-08-02
LT2702155T (lt) 2017-05-10
CL2013003105A1 (es) 2014-08-01
SI2702155T1 (sl) 2017-07-31
EP3211082B1 (en) 2021-02-17
TWI698445B (zh) 2020-07-11
PT2702155T (pt) 2017-04-03
CN103620035B (zh) 2021-04-23
EP3211082A1 (en) 2017-08-30
DK3211082T3 (da) 2021-05-10
AU2017219156B2 (en) 2020-01-02
MX2019003089A (es) 2019-07-18
KR102055172B1 (ko) 2020-01-23
AU2012249851A8 (en) 2013-11-14
UA115652C2 (uk) 2017-12-11
SI3211082T1 (sl) 2021-08-31
TW201811812A (zh) 2018-04-01
JP6320292B2 (ja) 2018-05-09

Similar Documents

Publication Publication Date Title
MX2019003090A (es) Compuestos de microarn y metodos para modular la actividad de mir-21.
ECSP14028612A (es) Compuestos de microarn y metodos de modulacion de la actividad de mir-21
CO6761389A2 (es) Inhibidores de nampt y rock
ECSP14013153A (es) Compuestos inhibidores de metaloenzimas
UY33314A (es) Derivados de acido 1-amino-2-ciclopropiletilboronico
GT201300209A (es) Compuestos y composiciones como inhibidores de la trk
UY34051A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
MX2014013752A (es) Inhibidores de nampt.
MX2015012867A (es) Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
PH12014502513A1 (en) Nampt inhibitors
EP2709612A4 (en) COMPOSITIONS AND METHODS OF TREATMENT AND PREVENTION OF CANCER BY TARGETING AND INHIBITION OF CANCER STEM CELLS
MX348311B (es) Inhibidores nampt.
MX2015003701A (es) Composiciones para tratamiento.
DOP2014000046A (es) COMPOSICIONES Y MÉTODOS PARA TRATAR EL CÁNCER USANDO EL INHIBIDOR DE PI3Kbeta Y EL INHIBIDOR DE LA VÍA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
MX2014013758A (es) Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
TN2014000401A1 (en) Microrna compounds and methods for modulating mir-21 activity
CR20110540S (es) Gabinete de barra para estacionamiento